Number 5: Biosimilar insulin glargine struggles for market share in the UK, facing pricing challenges and prescriber inertia ...

Biosimilar LY01011 is equivalent to the reference product denosumab for treating bone metastases in solid tumors, demonstrating similar efficacy in reducing bone metabolism biomarkers, comparable ...

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...

Researchers analyze the quality of monoclonal antibody biosimilars in Japan, revealing variations that impact adoption and ...

The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and ...

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis ...

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

Number 5: Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, ...

Patent thickets hinder biosimilar access, driving up costs and delaying affordable treatments. Discover legislative solutions to enhance competition and patient care.

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases, and ophthalmic conditions.

Explore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization in this engaging podcast episode.